Ignite Creation Date:
2024-05-06 @ 8:18 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06339281
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-19
First Post:
2024-03-05
Brief Title:
A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctors Choice for Advanced Breast Cancer
Sponsor:
Li Huiping
Organization:
Peking University Cancer Hospital Institute
Study Overview
Official Title:
A Multicenter Clinical Study of Apatinib Mesylate in Combination With a Physicians Choice Regimen for Her-2 Negative HR-positive Progressive Breast Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Previous studies have found good efficacy of investigators choice of chemotherapy or endocrine drug in combination with apatinib mesylate in the treatment of her-2 negative chest wall metastatic advanced breast cancer and the present study proposes to further explore the efficacy of apatinib mesylate in her-2 negative HR-positive advanced breast cancer
Detailed Description:
In order to further explore the efficacy of apatinib mesylate in advanced breast cancer with negative her-2 and positive HR this study intends to carry out an observation study on the efficacy of apatinib mesylate combined with doctors choice scheme in the treatment of advanced breast cancer with negative her-2 and positive HR
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None